Investors
Quarterly Reports
Q3 2019 Report
Tuesday, 19 NovemberArctic Securities, Haakon VIIs gate 5, OsloThe webcast will be streamed LIVE and the recording will be available after LIVE session is finished.
Link to live webcastCorporate Presentation
H.C. Wainwright 21st Annual Global Life Sciences Conference
Sept 10th, 2019
Read More
Scientific Presentations
SITC 2019, Matthew Krebs et al
8 November 2019Maryland, USA
A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis
Read More
Annual Report 2018
BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.
Our annual report
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159